Pauls Dietrich John
Transaction: 08/10/2026
BUY
Change
+60,200
Price
Not reported
Filing
08/12/2026
Type
BUY
DiaMedica Therapeutics Inc.
DMAC • Biotechnology
$6.75
▲ +0.19 (+2.90%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$363.79M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 11.81Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:46 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$6.75
Change2.90%
Shares Out53.89M
Market Cap$363.79M
Enterprise Value$320.47M
52W Range5.14 - 10.42
Beta0.97
P/E-9.69
P/B9.49
P/FCF-11.51
EV/EBITDA-11.17
EV/FCF-10.14
Price$6.75
Change2.90%
Shares Out53.89M
Market Cap$363.79M
Enterprise Value$320.47M
52W Range5.14 - 10.42
Beta0.97
P/E-9.69
P/B9.49
P/FCF-11.51
EV/EBITDA-11.17
EV/FCF-10.14
Earnings Yield-10.32%
FCF Yield-8.69%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio11.81
Quick Ratio11.81
Revenue 5Y-100.00%
Target$8.33
Target Upside23.41%
Target Median$8.00
Target Range7.00 - 10.00
Volume139.86K
Avg Volume195.77K
EPS Surprise-0.02
Investment DNA
How strong this company looks for long-term investors
39
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
48/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 11.81Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 6 analyst votes · 2026-09-05
100/100
Bullish
Bullish
6
Hold
0
Bearish
0
Price Target
2026-08-13
Low
$7.00
Mean
$8.33
Median
$8.00
High
$10.00
Insider Transactions
Recent executive and insider activity
Semba Charles Pauling
Transaction: 01/02/2026
BUY
Change
+3,355
Price
$8.42
Filing
01/06/2026
Type
BUY
Giuffre Randall Michael
Transaction: 01/02/2026
BUY
Change
+6,175
Price
$8.42
Filing
01/06/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Pauls Dietrich John | BUY | +60,200 | Not reported | 08/10/2026 | 08/12/2026 |
| Semba Charles Pauling | BUY | +3,355 | $8.42 | 01/02/2026 | 01/06/2026 |
| Giuffre Randall Michael | BUY | +6,175 | $8.42 | 01/02/2026 | 01/06/2026 |
| Parsons James T. | BUY | +10,095 | $8.42 | 01/02/2026 | 01/06/2026 |
| STAHLBERG JAN | BUY | +73,099 | $8.57 | 11/25/2025 | 12/08/2025 |
| STAHLBERG JAN | BUY | +40,253 | $7.89 | 11/24/2025 | 12/08/2025 |
| STAHLBERG JAN | BUY | +208,872 | $7.41 | 11/21/2025 | 12/08/2025 |
| STAHLBERG JAN | BUY | +128,426 | $7.41 | 11/20/2025 | 12/08/2025 |
| STAHLBERG JAN | BUY | +240,352 | $7.21 | 11/19/2025 | 12/08/2025 |
| STAHLBERG JAN | BUY | +182,882 | $6.75 | 11/18/2025 | 12/08/2025 |
| STAHLBERG JAN | BUY | +187,393 | $6.52 | 11/17/2025 | 12/08/2025 |
| Parsons James T. | SELL | -12,000 | $2.20 | 11/21/2025 | 11/25/2025 |
| Parsons James T. | BUY | +12,000 | $2.20 | 11/21/2025 | 11/25/2025 |
| Krop Julie | OTHER | 0 | Not reported | 08/11/2025 | 11/03/2025 |
| Krop Julie | BUY | +450,000 | $4.58 | 08/11/2025 | 11/03/2025 |
| STAHLBERG JAN | BUY | +50,772 | $6.00 | 08/27/2025 | 09/04/2025 |
| STAHLBERG JAN | BUY | +59,648 | $6.00 | 08/26/2025 | 09/04/2025 |
| STAHLBERG JAN | BUY | +338,265 | $6.00 | 08/25/2025 | 09/04/2025 |
| STAHLBERG JAN | BUY | +59,788 | $5.96 | 08/22/2025 | 09/04/2025 |
| STAHLBERG JAN | BUY | +48,172 | $5.96 | 08/21/2025 | 09/04/2025 |